Filing Flows › Lipocine (LPCN) › Q2 2026
Lipocine (LPCN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Lipocine (LPCN) reported revenue of $190K for the second quarter 2026 (Q2 2026), -69% from a year earlier and +59% from the quarter before.
Lipocine, Q2 2026: revenue $190K (-70% year over year), net loss $2.6M, operating cash flow −$3.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $190K | +59% | -69% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$2.6M | — | — |
| Operating cash flow | −$3.0M | — | — |
What changed
Revenue was $190K in Q2 2026, down 69% year over year and up 59% from the previous quarter.
Operating costs exceeded revenue by $2.8M, an operating margin of -1495.1%. Total costs grew 0% against a revenue fall of 69%. The fastest-growing cost line was General & admin (+11%). The quarter ended with a net loss of $2.6M, narrower than the previous quarter's $3.7M loss.
Operating cash flow was −$3.0M. Non-cash charges added back $15K of depreciation and amortization and $58K of share-based compensation. Working capital and other items used $479K.
Questions
What was Lipocine's revenue in the second quarter 2026?
Lipocine (LPCN) reported revenue of $190K for the second quarter 2026 (Q2 2026), -69% from a year earlier and +59% from the quarter before.
Source: Lipocine 10-Q on SEC EDGAR.